About CoTherix
CoTherix is a company based in San Francisco (United States) founded in 2000 was acquired by Actelion in November 2006. CoTherix has raised $55 million across 1 funding round from investors including Actelion, Frazier Healthcare Partners and Thomas Weisel Partners. CoTherix operates in a competitive market with competitors including Actelion, Aerovate Therapeutics, Vivus, Centessa Pharmaceuticals and Biosion, among others.
- Headquarter San Francisco, United States
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of CoTherix
CoTherix has successfully raised a total of $55M through 1 strategic funding round. The most recent funding activity was a Series C round of $55 million completed in October 2003. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in CoTherix
CoTherix has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include Actelion, Frazier Healthcare Partners and Thomas Weisel Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Biotech funding, drug development support, and investment in life sciences.
|
Locked | Locked | Locked | |
|
Healthcare sector private equity investments are managed by the firm.
|
Locked | Locked | Locked | |
|
Venture capital firm focused on healthcare companies
|
Locked | Locked | Locked |
Investor details for CoTherix
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by CoTherix
Investment portfolio details for CoTherix
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - CoTherix
Detailed financials for CoTherix
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cotherix Comparisons
Peer comparison for CoTherix
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of CoTherix
CoTherix operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Actelion, Aerovate Therapeutics, Vivus, Centessa Pharmaceuticals and Biosion, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Innovative treatments for orphan diseases are discovered, developed, and commercialized.
|
|
| Locked | Locked | Locked |
Therapeutic solutions for pulmonary arterial hypertension are developed.
|
|
| Locked | Locked | Locked |
Developer of therapeutic solutions for obesity and sexual health
|
|
| Locked | Locked | Locked |
Medicines for sleep-wake, neurological, neurodegenerative, and psychiatric disorders are developed.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics are developed for treating various diseases.
|
Detailed competitors of CoTherix
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cotherix
Complete news archive for CoTherix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about CoTherix
CoTherix was founded in 2000 and raised its 1st funding round 3 years after it was founded.
CoTherix is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
CoTherix is a funded company, having raised a total of $55M across 1 funding round to date.
CoTherix was established in 2000 in San Francisco, United States, within the biopharmaceutical sector. Therapeutics targeting cardiopulmonary and chronic diseases were licensed and developed by the company. Operations centered on inhaled treatments, including Ventavis (iloprost), approved for pulmonary arterial hypertension. The firm was acquired by Actellion in January 2007, concluding its independent activities.
CoTherix's top competitors include Aerovate Therapeutics, Actelion and Vivus.
CoTherix has 9 investors. Key investors include Actelion, Frazier Healthcare Partners, Thomas Weisel Partners, Turmeric Acquisition Corp, and Sofinnova.